Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease.
Cytomegalovirus (CMV) can be classified into 4 glycoprotein B (gB) genotypes, on the basis of sequence variation in the UL55 gene. We assessed the effect that CMV gB genotype has on virologic and clinical response to therapy, in 50 solid-organ-transplant recipients with CMV disease. CMV loads were determined at regular intervals after the start of therapy. Genotype results were correlated with CMV-load kinetics in response to therapy with ganciclovir. At the onset of treatment, the distribution of CMV gB genotypes was as follows: gB1, 19/50 (38%); gB2, 9/50 (18%); gB3, 12/50 (24%); gB4, 2/50 (4%); and mixed-genotype infection, 8/50 (16%). Between viral genotype groups, time to clearance of CMV, failure to clear CMV, and calculated CMV-load half-life after the start of therapy were not significantly different. The CMV gB genotype did not affect the rate of disease recurrence or occurrence of tissue-invasive disease. It appears that the gB genotype, which causes CMV disease, does not significantly influence CMV-load kinetics or clinical response to therapy.
Humar
Atul
A
Department of Medicine, Division of Multi-Organ Transplantation, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. Atul.Humar@uhn.on.ca.
Kumar
Deepali
D
Gilbert
Christian
C
Boivin
Guy
G
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000821:virology; D015774:Ganciclovir / Q000494:pharmacology / Q000627:therapeutic use; D012008:Recurrence; D014180:Transplantation; D014759:Viral Envelope Proteins / Q000235:genetics*; D019562:Viral Load
D000998:Antiviral Agents; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus; D015774:Ganciclovir